Paid Development Method Definition & Meaning | Insurance Term | CSIMarket
CSI Market
Sign In | Register

Glossary

Paid Development Method

Insurance Term

Paid Development Method is a technique that is used by insurance companies to determine the amount of money that should be paid in return for an insurance policy. The method involves evaluating the risks involved in the insurance policy and then calculating the probability of the risks occurring. This probability calculation is then used to determine the amount of money that the policyholder should pay for the insurance policy.

The Paid Development Method is primarily used in the insurance industry to determine the premium charges that should be levied on a particular insurance policy. The method takes into account various factors such as the age, health, occupation, income level, and lifestyle of the policyholder, along with the potential risks involved in the policy, to arrive at a premium that is fair to both the policyholder and the insurance company.

The Paid Development Method is used in a variety of insurance policies, including life insurance, health insurance, and property and casualty insurance. The method allows insurance companies to offer a wide range of insurance products at varying prices that are based on the calculated risks of the policyholders.

Overall, the Paid Development Method is an important tool in the insurance industry that helps to ensure that insurance policies are priced fairly and competitively while also taking into account the risks involved in the policy.


More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P